R&D Agentic AI and the human element: Building trustworthy autom... The future of clinical trials isn’t about replacing people. It’s about empowering them with smarter tools.
R&D Results, reality, and recalibration: Unpacking AI hype at SC... SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.
R&D Why the government’s latest funding push is critical to the ... Many of the UK’s most promising life sciences innovations continue to face persistent funding challenges, made worse by an increasingly volatile globa
R&D Navigating development in a complex molecule world For decades, the pharmaceutical industry has relied on accelerated development and manufacturing timelines to bring new therapies to patients quickly.
R&D Changing Faces: Board of Directors, January 2026 January was a relatively quiet month for Board news, but there were some notable moves here and there.
R&D On JPM2026 and healthcare investment today, with Jonah Comst... Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
